Wanbury share price today

Wanbury Ltd's share price was ₹192.41 at the close on 4 November 2026. It has been falling for 5 weeks. That is 21.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹177 and ₹333, and at that close it sat 10% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Wanbury Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 14 weeks running.

Over the last 11 years the share price moved +377% while the NIFTY 500 moved +257%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 31 July 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

1. Profit fell in the June 2026 quarter

   Profit was ₹3 crore, -76% on a year earlier (₹13 crore), after 5 quarters of growth.

3. Lowest operating margin in 8 quarters

   Operating margin was 9.8% in the June 2026 quarter, against 15% a year earlier.

For April to June 2026 (the quarter ended 30 June 2026), Wanbury reported revenue of ₹166 crore, up 1.5% from ₹163 crore a year earlier, and a profit of ₹3.24 crore, down 76.0% from ₹13.5 crore.

Wanbury results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Wanbury closed at ₹192.41 on 4 November 2026, down 22.1% from ₹246.90 a year earlier (7 November 2025) and up 153.7% over five years. Its highest weekly close since February 2016 was ₹332.50 on 24 July 2026.

Wanbury share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

564 weekly closes from 26 February 2016 to 4 November 2026.

4 Nov 2026: Wanbury closed at ₹192.41, up 1.4% on the week and down 3.3% on the month. Results for April to June 2026: Revenue up 1.5% and profit down 76.0% on a year earlier.

Earlier

• Our read, 31 May 2026: A legacy API manufacturer turning a financial corner through debt halving and Tanaku facility ramp-up, but the transition from generic volume to specialty margin is unproven at scale.

Our read of the business

Debt reduced ~75% from peak ~700 Cr; borrowing cost down from 22.5% to 12.5%, finance cost relief is the dominant driver of profit recovery, not operational margin expansion.,Tanaku facility (Andhra Pradesh) achieved first commercial anaesthetic API shipment to Europe in October to December 2025; management goals ~100 Cr incremental revenue by FY27 from 4 new molecules/year.,operating margin expanded from 8% (FY24) to 13% (FY25) to 16% (9M FY26), margin recovery tied to both mix improvement and operating leverage on existing 386 KL reactor capacity.

Latest quarter: Tanaku first commercial shipment, profit 1,194%, finance cost relief and API volume drive the number.

Our read after the latest results, written 31 May 2026.

Wanbury has paid no dividend on the NSE since 1 April 2021, the start of the period we checked.

No. Wanbury Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

Wanbury's management made 0 promises we could check against what it later reported.

Our read after the latest results, written 31 May 2026.

What is changing at Wanbury, from the latest results and calls: debt cost relief (ncd refinancing), tanaku facility, specialty api ramp and operating margin expansion via yield and solvent recovery.

• Debt Cost Relief (NCD Refinancing). Borrowing cost cut from 22.5% to 12.5% from March 2025, finance cost fell from 10 Cr/quarter (October to December 2024) to 7 Cr/quarter (October to December 2025). ~75% debt reduction from 700 Cr peak. ⚠ estimate
• Tanaku Facility, Specialty API Ramp. Tanaku facility first commercial anaesthetic API shipment to Europe dispatched October to December 2025; goals ~100 Cr incremental revenue, 4 new molecules/year from FY27. ⚠ estimate
• Operating margin Expansion via Yield and Solvent Recovery. Operating margin 16% in October to December 2025 vs 11% in October to December 2024 (+500 basis points on a year earlier); driven by better yields, solvent recovery systems, and higher-margin SKU mix. ⚠ estimate
• Regulated Market Expansion (USFDA / ANVISA / MFDS-Korea). 6th USFDA inspection at Patalganga passed with zero 483 observations; ANVISA Brazil GMP cert for Tanaku; Korea MFDS Patalganga clearance April 2026. Three major regulators clean simultaneously. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the latest results, written 31 May 2026.

First commercial shipment dispatched October to December 2025 but management's 100 Cr goal for FY27 implies an 8-10x ramp from one batch.

The main risks

• Tanaku Revenue Ramp Slippage: First commercial shipment dispatched October to December 2025 but management's 100 Cr goal for FY27 implies an 8-10x ramp from one batch. ✓ fact
• Finance Cost Floor, profit Growth Decelerates: Finance cost savings are the dominant FY26 profit driver. At 7 Cr/quarter, interest expense is near floor. Future profit growth needs genuine operating leverage. ✓ fact
• Generic API Pricing Pressure: Antidiabetic molecules (Metformin: 11% global share; Sertraline: 30% global share) are high-volume generics with inherent pricing pressure from Chinese manufacturers. ✓ fact
• Low Promoter Conviction: Promoter stake flat at 39.6-39.8% over 6 quarters despite a clear turnaround. ✓ fact

Our read after the latest results, written 31 May 2026.

When Wanbury reports July to September 2026, these are the 5 checks that show whether the story is still on course. First: Tanaku revenue contribution in April to June 2026 concall; second customer off-take announcement.

Wanbury is on one of our India lists: Pharma stocks.

Wanbury Ltd earned ₹3.2 Cr of net profit in the Jun 2026 quarter, −76.0% on the same quarter a year earlier. Full-year FY26 profit was ₹66.0 Cr. That is 2.0% of the quarter's revenue. The same quarter a year earlier earned ₹13.5 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹66.0 Cr (+112.9% on the year before).

Why profit moved: revenue changed +1.5% on a year earlier and the margin moved −5.2 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +303.0% and revenue +4.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Wanbury Ltd reported ₹166 Cr of revenue in the Jun 2026 quarter, +1.5% on the same quarter a year earlier. Over 10 years it has grown 4.5% a year on average. The last full year, FY26, came in at ₹650 Cr. The last four reported quarters add to ₹653 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. The formulations business, representing 12% of FY25 revenue, turned EBITDA positive in 9M FY26. Strategy involves transitioning from acute to specialty/chronic segments and geographical expansion into new markets. Field force build-out is planned for scale-up in FY27. The risk remains that this is a small segment (70 Cr FY25) and recurring profitability is not yet demonstrated across a full year.

FY26 revenue was ₹650 Cr, +8.3% on the year before.

Recent pace: the last four quarters grew +4.5% on average, against 4.5% a year over the longer run, so this year is growing at about the same pace as its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +3.6%, against +7.9% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +30.0%, against +44.5% a year (rolling over).

Wanbury Ltd's operating margin was 9.8% in the Jun 2026 quarter, 5.2 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between −18.0% and 16.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. Tanaku facility in Andhra Pradesh cleared ANVISA (Brazil) GMP audit with zero observations. First commercial shipment of high-potent anaesthetic API to a European customer dispatched in Q3 FY26. Management goals ~100 Cr revenue contribution and full commercial production by FY27. The product portfolio covers antitussive, anticoagulant, anaesthetic, and antidepressant molecules, regulated-market focused. Revenue is nascent and the milestone tracking gate is whether Tanaku exceeds 50 Cr revenue in FY27.

Why the margin moved: operating margin changed −5.2 percentage points on the year while gross margin changed −1.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 50% of Wanbury Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹32.0 Cr of operating cash against ₹66.0 Cr of profit. After ₹62.0 Cr of spending on assets, free cash was −₹30.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 50% of profit came in as cash: the cash cycle got 153 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 153 days longer. The next section looks at where the cash is stuck.

Wanbury Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 6 days in FY26, up from −147 days in FY21. It spent ₹125 Cr on assets over the last 3 years. Customers take 80 days to pay, and stock sits for 67 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹650 Cr, each day of that cycle ties up about ₹1.8 Cr, so roughly ₹11.0 Cr is tied up in the business at any time.

FY26: customers took 80 days to pay and stock sat for 67 days, about 2.2 months of sales sitting as stock, for a full cycle of 6 days, longer than FY21's −147.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 67 days. Customers pay about 80 days after that. Suppliers are paid at 142 days. Together that makes the 6-day cycle.

Spending on assets: ₹125 Cr over the last 3 years, against ₹40.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹25.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Wanbury Ltd's P/E is 11.4×, near the low end of its own history: it has been lower only 19% of the time. Its usual P/E (the middle reading) is 20.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹16.01.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.